EANS-News: SYGNIS Pharma AG SYGNIS is granted the European and US patent for a
very versatile and efficient drug screening platform
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Patents, Copyright & Trademarks
Heidelberg (euro adhoc) - Press Release
SYGNIS is granted the European and US patent for a very versatile and efficient
drug screening platform
- The patents protect a new procedure for screening and characterizing drugs in
development, based on detection of protein-protein interactions
- Detection of protein-protein interaction is becoming increasingly important
for developing new drugs as such technologies can simplify assays and enable
screening for new drugs with a fully novel approach
- SYGNIS' new technology broadens the possibilities for obtaining novel drugs
- SYGNIS intends to license the new technology to a distribution partner
- SYGNIS concluded its merger with the Spanish company X-Pol, a member of the
GENETRIX Group, in December last year
Heidelberg, 15 January 2013 - The biotech company SYGNIS Pharma AG (Frankfurt:
LIO1; ISIN: DE000A1RFM03; Prime Standard) has been granted the European and US
patent for a new basic technology for the detection of protein-protein
interactions, a screening platform for the development of novel drugs. In the
words of SYGNIS' CEO, Pilar de la Huerta, "the technology will be licensed to a
distribution partner and we expect to see our first revenues during the current
financial year 2013."
Protein-protein interactions falls within the scope of proteomics, a field that
is growing in importance for research into new customized drugs. SYGNIS' new
platform can be used to improve the characterization of new drugs in
development and identification of new therapeutic targets. SYGNIS' technology
will increase the potential for generating better drugs within the customized
drug development field. Following its merger with the Spanish company X-Pol,
which forms part of the GENETRIX Group, SYGNIS aims to become a key player in
the growing market for molecular tools and personalized medicine.
SYGNIS aims to use these patents, together with its recent company restructuring
and successful implementation of the polymerase QualiPhiTM, to enhance the
impetus it announced on its merger with X-Pol and become a prominent player in
the growing market for new DNA tools and customized drugs, a sector that has
seen a two-digit growth rate over the last few years. According to sources from
SYGNIS, this transformation will enable it to obtain its first revenues in 2013
and operating profit in successive years.
For further information please contact:
Peter Willinger
CFO
SYGNIS Pharma AG
Tel.: +49 6221 454 836
E-mail: peter.willinger@sygnis.de
About SYGNIS Pharma AG: www.sygnis.de
SYGNIS Pharma AG (Heidelberg, Germany) is a biotech company listed in the Prime
Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).
According to the 2012 newly defined business strategy, the Company focuses on
the development and marketing of novel technologies in molecular biology, e.g.
in the field of DNA amplification and sequencing. For the key product
"QualiPhiTM", an improved polymerase for amplifying DNA, an exclusive worldwide
license has been granted to Qiagen.
### Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions of
future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are subject
to known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or implied
predictions contained in such statements. SYGNIS does not undertake to publicly
update or revise these statements in the light of new information or future
results or for any other reason. ###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1RFM03
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English